Header
- Model name
- Advanced Cardiovascular Risk
- Developer
- Zenlo LLC
- Release stage
- Research Tool (not FDA-cleared)
- Version
- 1.0
- Availability
- United States
- Regulatory status
- Not applicable — academic and transparency positioning
- Pattern slug
- advanced_cvd_risk
- Biomarkers
- APOB, LPA, HOMOCYSTEINE, HSCRP
This document follows the CHAI Applied Model Card format (v0.1).
Summary
The Advanced Cardiovascular Risk pattern evaluates Apolipoprotein B, lipoprotein(a), homocysteine, and high-sensitivity CRP — markers associated with residual cardiovascular risk beyond basic lipid panels. Deterministic rules flag elevations against pattern-specific thresholds; any qualifying abnormality fires the pattern. Claude Haiku 4.5 synthesizes physician-facing narrative on advanced lipid and inflammatory risk markers. For licensed functional-medicine physicians, this is supportive clinical decision support — it does not replace basic lipid management, family-history assessment, or coronary artery calcium scoring. Outputs highlight advanced markers warranting specialist correlation, not automated treatment decisions.
Uses & Directions
Intended use
Clinical decision support for licensed physicians reviewing advanced cardiovascular risk markers in adult panels.
Primary users
Licensed functional medicine physicians and similarly qualified clinicians.
How to use
Review advanced markers with basic lipids, family history, blood pressure, and guideline-directed risk assessment.
Target population
Adults aged 18 and older in the United States.
Out of scope
- Direct patient use without physician oversight
- Pediatric populations
- Standalone diagnosis or statin initiation
- Replacement for coronary imaging or functional testing
Warnings
Clinical risk level
Low — supportive tool; the treating physician retains full clinical judgment and responsibility.
Known limitations
- Lp(a) is largely genetically determined; single measurements guide long-term risk, not acute changes.
- ApoB assays and reference ranges vary across laboratories.
- Homocysteine associations with CVD are modified by B-vitamin status.
Validation note
Validation pending — a Tier A NHANES validation run has not yet been completed for this pattern. Distribution, agreement, and fairness results will be published here when available.
Trust Ingredients
AI system facts
- Deterministic pattern detector (advanced_cvd_risk) plus Claude Haiku 4.5 for narrative synthesis
- Primary inputs: ApoB, Lp(a), homocysteine, and hs-CRP from structured extraction.
- Output: Pattern flag plus narrative on advanced cardiovascular marker abnormalities.
Security & compliance
- Anthropic Business Associate Agreement with zero-data-retention configuration
- HIPAA-aligned design; no patient data used for model training
Ongoing maintenance
Versioned, transparent, and reproducible via a public independent audit harness (see Resources).
Transparency
Self-funded development; no third-party sponsor for this pattern card.
Key Metrics
Usefulness / Efficacy
Zenlo's detection approach was benchmarked across five models in a separate study; see the medRxiv preprint in Resources. No per-pattern efficacy metric is published for this pattern.
Source: 5-model benchmark, medRxiv MEDRXIV/2026/346284
Fairness / Equity
Validation pending — a Tier A NHANES validation run has not yet been completed for this pattern. Distribution, agreement, and fairness results will be published here when available.
Safety / Reliability
- Supportive-only; not intended as a standalone diagnostic
- Physician authorization required before clinical use
- Deterministic detector is reproducible for inputs: APOB, LPA, HOMOCYSTEINE, HSCRP
Resources
- medRxiv preprint MEDRXIV/2026/346284 — 5-model benchmark (system-level detector evaluation)
- JAMIA Open submission JAMIO-2026-0120 (under review)
- Independent audit harness: github.com/dimashibakov/zenlo-audit — reproducibility manifest, NHANES 2015–2016 cycle, harness commit c10afe8
Footer
Note: The mention or sharing of any examples, products, organizations, or individuals does not indicate any endorsement of those examples, products, organizations, or individuals by the Coalition for Health AI (CHAI).